avapro has been researched along with Lupus Erythematosus, Systemic in 2 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A substantial number of patients with lupus nephritis (LN) are refractory to conventional glucocorticoid (GC) treatment." | 5.39 | Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide. ( Amano, K; Chino, K; Ito, T; Kato, H; Kondo, T; Kurasawa, T; Nagasawa, H; Nishi, E; Nishimura, K; Ogawa, H; Okuyama, A; Sakai, R; Shibata, A; Takei, H, 2013) |
| "A substantial number of patients with lupus nephritis (LN) are refractory to conventional glucocorticoid (GC) treatment." | 1.39 | Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide. ( Amano, K; Chino, K; Ito, T; Kato, H; Kondo, T; Kurasawa, T; Nagasawa, H; Nishi, E; Nishimura, K; Ogawa, H; Okuyama, A; Sakai, R; Shibata, A; Takei, H, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kurasawa, T | 1 |
| Nagasawa, H | 1 |
| Nishi, E | 1 |
| Takei, H | 1 |
| Okuyama, A | 1 |
| Kondo, T | 1 |
| Nishimura, K | 1 |
| Sakai, R | 1 |
| Shibata, A | 1 |
| Chino, K | 1 |
| Ogawa, H | 1 |
| Ito, T | 1 |
| Amano, K | 1 |
| Kato, H | 1 |
| Sahin, G | 1 |
| Korkmaz, C | 1 |
| Işiksoy, S | 1 |
| Yalçin, AU | 1 |
2 other studies available for avapro and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide.
Topics: Adolescent; Antihypertensive Agents; Biphenyl Compounds; Cyclophosphamide; Cyclosporine; Drug Therap | 2013 |
Autoimmune hypothyroidism and lupus-like syndrome.
Topics: Adult; Arthritis; Azathioprine; Biphenyl Compounds; Complement C3; Complement C4; Complement System | 2010 |